Pharmacokinetic Characterization of Rituximab in Patients with Glomerular Diseases
Albuminemia and proteinuria affect rituximab t 1/2 and drug exposure in patients with glomerular diseases. Patients with proteinuria >2.4 g /24h may require higher frequent dosing for adequate rituximab exposure. Establishing an optimal dosing regimen in this population remains warranted.
Authors
- Irene Agraz Pamplona
- Sonia García García
- Manuel Hernández González (ORCID: https://orcid.org/0000-0002-6936-9661)
- Roger Colobrán
- María José Soler (ORCID: https://orcid.org/0000-0003-3621-0766)
- María Larrosa-García (ORCID: https://orcid.org/0000-0001-6492-0568)
- Mónica Martínez‐Gallo
- José Bruno Montoro Ronsano (ORCID: https://orcid.org/0000-0003-4390-2189)
- María Teresa Sanz Martínez
- Roxana Paola Bury Macías
Institutions
- Universitat Autònoma de Barcelona (ES)
- Vall d'Hebron Institut de Recerca (ES)
- Vall d'Hebron Hospital Universitari (ES)
Publication Details
- Journal
- Therapeutic Drug Monitoring
- Published
- 2025-06-27
- DOI
- https://doi.org/10.1097/ftd.0000000000001353
- Citations
- 1
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 1.43